Mounjaro and TTC: What You Need to Know Before Trying to Conceive

Step 1: Understand why Mounjaro and active TTC don't overlap

The reason tirzepatide is not recommended when trying to conceive is straightforward: it has not been studied in human pregnancies, and data from animal studies raised concerns about foetal development. That is not unusual for newer medicines, but it does mean there is no evidence base to call it safe during the window when a fertilised egg is implanting and earliest development is occurring. The precautionary position, reflected in the product's licensed guidance, is that treatment should stop before conception is attempted.

There is also a practical consideration. Mounjaro slows gastric emptying and reduces appetite substantially. Adequate nutrition in the weeks surrounding conception matters, and the nausea that can accompany early treatment or dose increases is an added complication in that context. Your prescriber will weigh all of this when you raise TTC plans with them, which, if you are currently on treatment, is the conversation to have sooner rather than later. The clinical team at nume reviews every patient's full picture before any prescription decision, and that includes conversations about fertility plans.

If you want background on the broader profile of this medicine, the NHS patient information for tirzepatide sets out the not-recommended groups plainly, including pregnancy and breastfeeding.

Step 2: Sort out contraception before your next dose

This step surprises many people. If you are on Mounjaro and not yet ready to conceive but planning to be in the future, you still need to think carefully about contraception right now. Tirzepatide slows how quickly your stomach empties, which can reduce how well an oral contraceptive pill is absorbed, particularly in the first four weeks of treatment and for four weeks after any dose increase.

UK guidance, reflected on the NHS England weight-management injections page, advises adding a non-oral contraceptive method during those windows. That means condoms, a patch, a ring, a coil, or an implant alongside your pill, not instead of it, unless you switch methods entirely. This is the same guidance that applies to anyone on tirzepatide who is not planning pregnancy, and it matters doubly when you are at the stage of thinking about when to stop.

The interaction with oral contraception is also relevant for anyone considering HRT alongside Mounjaro. Our page on Mounjaro and HRT covers that territory in more detail if it applies to you.

Step 3: Plan the wash-out and what comes next

Stopping Mounjaro before trying to conceive is not an abrupt exit, it is a planned step. UK guidance recommends a wash-out period, meaning a gap between your last dose and beginning to try. The precise length is something your prescriber sets based on your dose, how long you have been on treatment, and your overall health picture. Do not assume a fixed number of weeks applies universally; this is genuinely individual.

The other thing to plan is what happens to your weight management during that period. Weight that has been lost on tirzepatide can return if no other strategies are in place, and starting from a lower, healthier weight before pregnancy is itself considered beneficial. Your prescriber can discuss bridging approaches, dietary support, and when it might be appropriate to revisit treatment after any pregnancy and breastfeeding period concludes.

If you are weighing up the cost and structure of private treatment during this planning phase, our page on UK Mounjaro pricing gives honest context on what treatment costs and what to watch out for. And if you want to understand the broader landscape of what Mounjaro is and how it works, that overview is a useful grounding before any conversation with a prescriber.

Step 4: Re-engage with clinical support when the time is right

After pregnancy and any period of breastfeeding, Mounjaro may be an option again, but that requires a fresh clinical assessment. Tirzepatide is not recommended while breastfeeding, because it is not known whether it passes into breast milk and what effect, if any, that might have on an infant.

When you are ready to return to weight management treatment, a new consultation is the starting point. At nume, there are no long waiting lists and no subscriptions, each prescription cycle is reviewed independently. For those transferring back after a break, our prescribers check current weight, any changes in health conditions, and the right starting dose. The pen itself arrives by tracked DPD delivery in plain, unbranded packaging, usually the next working day after approval.

It is also worth knowing that some conditions that can affect fertility (including polycystic ovary syndrome and insulin resistance) are among the weight-related conditions that may be considered during eligibility assessment. Our weight loss treatment overview explains the eligibility criteria in plain terms. For questions specific to your situation, the faqs page covers common queries, or you can reach the team directly through our contact page.

If you have other health conditions alongside TTC plans (such as multiple sclerosis or IBS) it is worth reading the relevant guidance: our pages on Mounjaro and MS and Mounjaro and IBS cover those intersections with the same level of clinical detail. Those planning around fertility may also find it useful to read about how optic neuritis relates to Mounjaro, and separately our page on Mounjaro and erectile dysfunction addresses questions that sometimes arise for male partners during this planning period.